Research faces a conundrum. While the use of CAR T-cell therapy has expanded for patients, relapse rates remain high. A recent study found 57% of all patients relapsed within a year of treatment. According to Liang et al Journal of Hematology & Oncology, CD-19 specific CAR T cell therapy has significantly improved the outcome of patients with relapse/refractory diffuse large B-Cell lymphoma (R/R DLBCL), resulting in durable remissions in approximately 40% of heavily pre-treated patients. Despite these encouraging results, nearly half of the patients could not achieve durable responses after CD19-CAR T therapy, and a significant proportion of patients will eventually relapse.
Clearly, as data from a larger patient population is published, a high risk of relapse has again emerged as a formidable obstacle on the road to long-term survival.
The need for effective therapies to lessen relapse – along with the need for rapid and cost-effective manufacturing — are among the most pressing matters we face. It is not an overstatement to say we’re in need of cell therapy that ultimately doesn’t lead to more treatment.
Luminary Therapeutics is keenly focused on reducing relapse rates in CAR-T therapies. We bring energized attention and novel solutions to three key industry challenges: Antigen Escape, T Cell Exhaustion and an Allogeneic platform.
Copyright © 2022 All Rights Reserved by Luminary Therapeutics.